Morningstar

Takeda Pharmaceutical Raises Annual Guidance

Provided by Dow Jones

By Kosaku Narioka 




  Takeda Pharmaceutical raised its annual earnings forecasts, after swinging to a net profit in the second quarter. 



  The Japanese drugmaker on Thursday reported net profit of 192.4 billion yen, equivalent to $1.22 billion, for the three months ended September, compared with a net loss of Y11.8 billion a year earlier. That beat estimated net profit of Y67.8 billion in a poll of analysts by data provider Visible Alpha. 



  The year-earlier bottom line was weighed by impairment charges related to the cell-therapy research it discontinued as part of a strategic portfolio review. 



  Second-quarter revenue grew 6.7% from a year earlier to Y1.187 trillion. Sales of ulcerative colitis drug Entyvio climbed 11% to Y273.4 billion and sales of plasma-derived products rose 8.1% to Y277.2 billion. 



  For the fiscal year ending March 2027, it projected a 4.3% rise in revenue to Y4.700 trillion and net profit of Y209.00 billion, compared with a net loss the previous year. The company previously projected revenue of Y4.640 trillion and net profit of Y166.00 billion for this fiscal year. 





  Write to Kosaku Narioka at kosaku.narioka@wsj.com 





  (END) Dow Jones Newswires



  October 29, 2026 03:25 ET (07:25 GMT)


Copyright (c) 2026 Dow Jones & Company, Inc.
  

					The articles, information, and content displayed on this webpage may
					include materials prepared and provided by third parties. Such
					third-party content is offered for informational purposes only and
					is not endorsed, reviewed, or verified by Morningstar.
				
 

					Morningstar makes no representations or warranties regarding the
					accuracy, completeness, timeliness, or reliability of any third-party
					content displayed on this site. The views and opinions expressed in
					third-party content are those of the respective authors and do not
					necessarily reflect the views of Morningstar, its affiliates, or employees.
				
 

					Morningstar is not responsible for any errors, omissions, or delays
					in this content, nor for any actions taken in reliance thereon.
					Users are advised to exercise their own judgment and seek independent
					financial advice before making any decisions based on such content.
					The third-party providers of this content are not affiliated with
					Morningstar, and their inclusion on this site does not imply any
					form of partnership, agency, or endorsement.
				
 

				Popular
				
 
  
 
 
 
 
5 Stocks to Buy Trading at Big Discounts
 
Plus, what recent bond market volatility means for investors. 
 
 
David Sekera, CFA and Sarah Hansen 
 
 
 
2 Undervalued Stocks to Buy With Long-Term Growth Ahead
 
Defense spending and booming data center demand could provide powerful tailwinds for these 4-star stocks. 
 
 
David Sekera, CFA, Sarah Hansen, and Jess Bebel 
 
 
 
The Market May Be Too Pessimistic About This 4-Star Dividend Stock
 
Despite a looming patent cliff, a strong drug pipeline and 4.1% yield give investors reasons for optimism. 
 
 
Karen Andersen, CFA 
 
 
 
What 7 Key Market Indicators Are Telling Investors Right Now
 
US equity valuations have retreated from their recent highs, but all 7 major market indicators remain above their long-term averages. 
 
 
Amy C. Arnott, CFA 
 
 
 
There Are Three Paths Forward for the AI Boom. Two of Them Lead to Lower Interest Rates
 
Mass layoffs or a spending slowdown would likely require hefty Fed rate cuts. 
 
 
Preston Caldwell 
 
 
 
 

			Sponsor Center